| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| MOSAICC | 19-41 | Myeloproliferative neoplasms and non-blood relative/friend controls. |
|
DSSG Group: Acute Leukaemia
MK-1026-003
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK-1026-003 | 21-22 | Hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM) |
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM). |
HOVON 150
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| HOVON 150 | 19-18 | Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy |
This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy |